A  	A  	 DT	O
pilot  	pilot  	 NN	O
cohort  	cohort  	 NN	O
study  	study  	 NN	O
to  	to  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
feasibility  	feasibility  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
prevention  	prevention  	 NN	I-NP
science  	science  	 NN	I-NP
research  	research  	 NN	I-NP
among  	among  	 IN	O
men  	men  	 NNS	O
who  	who  	 WP	O
have  	have  	 VBP	O
sex  	sex  	 NN	O
with  	with  	 IN	O
men  	men  	 NNS	O
in  	in  	 IN	O
Dakar 	Dakar 	 NNP	B-NP
,  	,  	 ,	O
Senegal  	Senegal  	 NNP	O
Men  	Men  	 NNPS	B-NP
who  	who  	 WP	I-NP
have  	have  	 VBP	I-NP
sex  	sex  	 NN	I-NP
with  	with  	 IN	I-NP
men  	men  	 NNS	I-NP
( 	( 	 -LRB-	O
MSM 	MSM 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
disproportionately  	disproportionately  	 RB	O
burdened  	burdened  	 VBN	O
by  	by  	 IN	O
HIV  	HIV  	 NNP	B-NP
in  	in  	 IN	O
Senegal 	Senegal 	 NNP	O
,  	,  	 ,	O
across  	across  	 IN	O
sub-Saharan  	sub-Saharan  	 NNP	O
Africa  	Africa  	 NNP	O
and  	and  	 CC	O
throughout  	throughout  	 IN	O
the  	the  	 DT	O
world 	world 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
driven  	driven  	 VBN	O
in  	in  	 IN	O
part  	part  	 NN	O
by  	by  	 IN	O
stigma 	stigma 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
limits  	limits  	 NNS	O
health  	health  	 NN	B-NP
achievements  	achievements  	 NNS	I-NP
and  	and  	 CC	O
social  	social  	 JJ	B-NP
capital  	capital  	 NN	I-NP
among  	among  	 IN	O
these  	these  	 DT	O
populations 	populations 	 NNS	O
.  	.  	 .	O
To  	To  	 TO	O
date 	date 	 NN	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
limited  	limited  	 JJ	O
understanding  	understanding  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
feasibility  	feasibility  	 NN	O
of  	of  	 IN	O
prospective  	prospective  	 JJ	O
HIV  	HIV  	 NNP	B-NP
prevention  	prevention  	 NN	O
studies  	studies  	 NNS	O
among  	among  	 IN	O
MSM  	MSM  	 NNP	B-NP
in  	in  	 IN	O
Senegal 	Senegal 	 NNP	O
,  	,  	 ,	O
including  	including  	 VBG	O
HIV  	HIV  	 NNP	B-NP
incidence  	incidence  	 NN	O
and  	and  	 CC	O
cohort  	cohort  	 JJ	B-NP
retention  	retention  	 NN	I-NP
rates 	rates 	 NNS	I-NP
.  	.  	 .	O
One  	One  	 CD	O
hundred  	hundred  	 CD	O
and  	and  	 CC	O
nineteen  	nineteen  	 JJ	O
men  	men  	 NNS	O
who  	who  	 WP	O
reported  	reported  	 VBD	O
having  	having  	 VBG	O
anal  	anal  	 JJ	B-NP
sex  	sex  	 NN	I-NP
with  	with  	 IN	O
another  	another  	 DT	O
man  	man  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
past  	past  	 JJ	O
12  	12  	 CD	O
months  	months  	 NNS	O
were  	were  	 VBD	O
randomly  	randomly  	 RB	O
selected  	selected  	 VBN	O
from  	from  	 IN	O
a  	a  	 DT	O
sampling  	sampling  	 JJ	O
frame  	frame  	 NN	O
of  	of  	 IN	O
450  	450  	 CD	O
unique  	unique  	 JJ	O
members  	members  	 NNS	O
of  	of  	 IN	O
community  	community  	 NN	B-NP
groups  	groups  	 NNS	I-NP
serving  	serving  	 VBG	I-NP
MSM  	MSM  	 NNP	I-NP
in  	in  	 IN	O
Dakar 	Dakar 	 NNP	B-NP
.  	.  	 .	O
These  	These  	 DT	O
men  	men  	 NNS	O
were  	were  	 VBD	O
enrolled  	enrolled  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
15-month  	15-month  	 JJ	O
pilot  	pilot  	 NN	B-NP
cohort  	cohort  	 NNS	I-NP
study  	study  	 VBP	O
implemented  	implemented  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
community-based  	community-based  	 JJ	O
partner 	partner 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
included  	included  	 VBD	O
a  	a  	 DT	O
structured  	structured  	 JJ	O
survey  	survey  	 NN	B-NP
instrument  	instrument  	 NN	I-NP
and  	and  	 CC	O
biological  	biological  	 JJ	B-NP
testing  	testing  	 NN	I-NP
for  	for  	 IN	I-NP
HIV 	HIV 	 NNP	I-NP
,  	,  	 ,	O
syphilis  	syphilis  	 NN	O
and  	and  	 CC	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
virus  	virus  	 NN	I-NP
at  	at  	 IN	O
two  	two  	 CD	O
time  	time  	 NN	B-NP
points 	points 	 NNS	I-NP
.  	.  	 .	O
Baseline  	Baseline  	 NNP	O
HIV  	HIV  	 NNP	B-NP
prevalence  	prevalence  	 NN	O
was  	was  	 VBD	O
36.0 	36.0 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
43 	43 	 CD	O
/ 	/ 	 CD	O
114 	114 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
with  	with  	 IN	O
cumulative  	cumulative  	 JJ	O
HIV  	HIV  	 NNP	B-NP
prevalence  	prevalence  	 NN	O
at  	at  	 IN	O
study  	study  	 NN	B-NP
end  	end  	 NN	I-NP
being  	being  	 VBG	O
47.2 	47.2 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
51 	51 	 CD	O
/ 	/ 	 CD	O
108 	108 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
annualized  	annualized  	 JJ	O
incidence  	incidence  	 NN	B-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
16 	16 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
8 	8 	 CD	O
/ 	/ 	 CD	O
40  	40  	 CD	O
at  	at  	 IN	O
risk  	risk  	 NN	O
for  	for  	 IN	O
seroconversion  	seroconversion  	 NN	B-NP
over  	over  	 IN	O
15  	15  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
follow-up 	follow-up 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 VBD	I-NP
4.6-27.4 	4.6-27.4 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Thirty-seven  	Thirty-seven  	 JJ	O
men  	men  	 NNS	O
were  	were  	 VBD	O
lost  	lost  	 VBN	O
to  	to  	 TO	O
follow  	follow  	 VB	O
up 	up 	 RP	O
,  	,  	 ,	O
including  	including  	 VBG	O
at  	at  	 IN	O
least  	least  	 JJS	O
four  	four  	 CD	O
deaths 	deaths 	 NNS	O
.  	.  	 .	O
Men  	Men  	 NNS	O
who  	who  	 WP	O
were  	were  	 VBD	O
able  	able  	 JJ	O
to  	to  	 TO	O
confide  	confide  	 VB	O
in  	in  	 IN	O
someone  	someone  	 NN	O
about  	about  	 IN	O
health 	health 	 NN	O
,  	,  	 ,	O
emotional  	emotional  	 JJ	B-NP
distress  	distress  	 NN	I-NP
and  	and  	 CC	O
sex  	sex  	 NN	O
were  	were  	 VBD	O
less  	less  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
HIV  	HIV  	 JJ	B-NP
positive  	positive  	 JJ	O
( 	( 	 -LRB-	O
OR  	OR  	 NNP	O
0.36 	0.36 	 NNP	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.13 	0.13 	 CD	O
,  	,  	 ,	O
0.97 	0.97 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
High  	High  	 NNP	O
HIV  	HIV  	 NNP	B-NP
prevalence  	prevalence  	 NN	O
and  	and  	 CC	O
incidence 	incidence 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
mortality  	mortality  	 NN	O
in  	in  	 IN	O
this  	this  	 DT	O
young  	young  	 JJ	O
population  	population  	 NN	O
of  	of  	 IN	O
Senegalese  	Senegalese  	 NNP	O
MSM  	MSM  	 NNP	B-NP
indicate  	indicate  	 VBP	O
a  	a  	 DT	O
public  	public  	 JJ	B-NP
health  	health  	 NN	I-NP
emergency 	emergency 	 NN	I-NP
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
given  	given  	 VBN	O
the  	the  	 DT	O
high  	high  	 JJ	O
burden  	burden  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
and  	and  	 CC	O
rate  	rate  	 NN	O
of  	of  	 IN	O
incident  	incident  	 NN	O
HIV  	HIV  	 NN	B-NP
infections 	infections 	 NNS	O
,  	,  	 ,	O
this  	this  	 DT	O
population  	population  	 NN	O
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
appropriate  	appropriate  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
novel  	novel  	 NN	O
HIV  	HIV  	 NNP	B-NP
prevention 	prevention 	 NN	O
,  	,  	 ,	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
care  	care  	 NN	B-NP
approaches 	approaches 	 NNS	I-NP
.  	.  	 .	O
Using  	Using  	 VBG	O
a  	a  	 DT	O
study  	study  	 NN	O
implemented  	implemented  	 VBN	O
by  	by  	 IN	O
community-based  	community-based  	 JJ	O
organizations 	organizations 	 NNS	B-NP
,  	,  	 ,	O
there  	there  	 EX	O
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
feasibility  	feasibility  	 VBN	O
in  	in  	 IN	O
implementing  	implementing  	 VBG	O
interventions  	interventions  	 NNS	B-NP
addressing  	addressing  	 VBG	O
the  	the  	 DT	O
multiple  	multiple  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
risk  	risk  	 NN	O
among  	among  	 IN	O
MSM  	MSM  	 NNP	B-NP
in  	in  	 IN	O
this  	this  	 DT	O
setting 	setting 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
low  	low  	 JJ	O
retention  	retention  	 NN	O
across  	across  	 IN	O
arms  	arms  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
pilot  	pilot  	 NN	O
intervention 	intervention 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
cohort 	cohort 	 NN	B-NP
,  	,  	 ,	O
will  	will  	 MD	O
need  	need  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
addressed  	addressed  	 VBN	O
for  	for  	 IN	O
larger-scale  	larger-scale  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
to  	to  	 TO	O
be  	be  	 VB	O
feasible 	feasible 	 JJ	O
.  	.  	 .	O
